enGene Holdings Inc. (ENGN) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of enGene Holdings Inc. stock $1.87, price $1.75, upside +6.9%, quality 25 out of 100. Rating: fairly valued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer.
Show moreShow less
Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Stock analysis
enGene Holdings Inc. (ENGN) currently trades at $1.75, while our model-based Fair Value estimate is $1.87, so the stock looks roughly fairly valued today (gap 6.4%).
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $1.23 (bear) to $2.34 (bull), the price of $1.75 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.
enGene Holdings Inc. Common Stock reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$117M in FY2025.
Key figures
Market cap $122M Micro · EPS (TTM) $−2.07 · Return on equity −60.5% · Return on assets (EBIT) −26.5% (5-year average) · Free cash flow −$101M · Net cash $18.4M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).
What moves the price
The share trades about 86% below its 52-week high and 22% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 7%, ENGN screens richer than that median.
Fair Value models
Bear$1.23Fair Value $1.87Bull$2.34
Price $1.75 · Upside +6.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham)$1.45$2.20$2.7554
All 1 models by family
Asset-Based
NCAV (Graham)$1.45$2.20$2.7554
The fair value above starts from this blend and is adjusted for dilution from new shares.
In the last 6 months, one officer or director bought shares worth $10,051, on Sep 22, 2026.
BuyWilliam GrossmanInterim Chief Medical Officer, Director5,102 shares at $1.97$10,051Sep 22, 2026
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Compare enGene Holdings Inc. Common Stock with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 4/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score25 · Bottom 25%
Fair Value upside+6.9% · Top 25%
Profitability
Return on assets−53.0% · Bottom 25%
Operating margin (12 months)0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY)0.0% · Above median
Balance sheet
Debt / equity0.09× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "enGene Holdings Inc. Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/ENGN
Frequently asked questions
Is enGene Holdings Inc. (ENGN) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $1.87 versus a price of $1.75, about +7% upside (fairly valued).
What is the fair value of ENGN?
Our model-based fair value for enGene Holdings Inc. is $1.87 (as of Nov 6, 2026), built from audited fundamentals. The current price: $1.75.
What is the quality score of ENGN?
enGene Holdings Inc. has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for enGene Holdings Inc. (ENGN)?
Our model-based price target is the fair value of $1.87 (as of Nov 6, 2026) from 1 valuation models. Cautious scenario $1.23, optimistic scenario $2.34. It is a calculation from audited fundamentals, not an analyst target.
What is the enGene Holdings Inc. Common Stock stock forecast for 2026?
Our models put fair value at $1.87, about +7% upside versus a price of $1.75 (fairly valued). Cautious scenario $1.23, optimistic scenario $2.34. The calculation is refreshed regularly with new filings.
What is the intrinsic value of enGene Holdings Inc. (ENGN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For enGene Holdings Inc. it is $1.87 per share (as of Nov 6, 2026), against a price of $1.75. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is enGene Holdings Inc. Common Stock stock overvalued or undervalued in 2026?
As of Nov 6, 2026, ENGN trades below its calculated fair value: price $1.75, fair value $1.87, a gap of about +7% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ENGN?
No. The price is what the market pays today ($1.75); the fair value is what the company's own numbers justify ($1.87). For enGene Holdings Inc. the two are $0.1200 per share apart. That gap is exactly why we show both numbers side by side.
How much is enGene Holdings Inc. Common Stock worth?
The market values enGene Holdings Inc. at about $122M (market capitalisation, as of Nov 6, 2026). Per share that is $1.75; our models calculate a fair value of $1.87 per share.
What do the bullish and bearish scenarios say about ENGN?
Our models span a range for enGene Holdings Inc.: cautious scenario $1.23, base $1.87, optimistic $2.34 per share (as of Nov 6, 2026, price $1.75). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of enGene Holdings Inc. (ENGN)?
Balance-sheet figures for enGene Holdings Inc. (as of Nov 6, 2026): return on equity −60.5%, debt of 0.09 per unit of equity. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
How far is ENGN from its 52-week high?
enGene Holdings Inc. trades at $1.75, about 86% below its 52-week high of $12.17 and 22% above the low of $1.44 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $1.87 is for.
Which stocks are comparable to enGene Holdings Inc. Common Stock?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is enGene Holdings Inc. Common Stock stock attractive at the current price?
The data as of Nov 6, 2026: price $1.75, calculated fair value $1.87 (+7%), Quality Score 25/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ENGN calculated?
We run enGene Holdings Inc. through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $1.87 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. enGene Holdings Inc. currently trades 6% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of enGene Holdings Inc. (ENGN)?
The closing price on Nov 6, 2026 was $1.75. Our model-based fair value is $1.87, about +7% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with enGene Holdings Inc. Common Stock right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range ($1.23 to $2.34) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of enGene Holdings Inc.
How large is the market capitalisation of enGene Holdings Inc. (ENGN)?
The market capitalisation of enGene Holdings Inc. is $122M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of enGene Holdings Inc. (ENGN)?
Earnings per share at enGene Holdings Inc. are $−2.07. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of enGene Holdings Inc. (ENGN)?
The return on equity (ROE) of enGene Holdings Inc. is −60.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of enGene Holdings Inc. (ENGN)?
On an EBIT basis the return on assets of enGene Holdings Inc. is −26.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does enGene Holdings Inc. (ENGN) generate?
The free cash flow of enGene Holdings Inc. is −$101M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does enGene Holdings Inc. (ENGN) hold?
enGene Holdings Inc. holds more cash than debt, $18.4M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch enGene Holdings Inc. Common Stock in the live analysis
One click puts enGene Holdings Inc. Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 6, 2026
